New shot could tame high blood pressure – early trial underway
NCT ID NCT07297797
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests an injectable drug called HRS-9563 in 234 adults with mild to moderate hypertension. Participants are randomly assigned to receive either the drug or a placebo injection. The main goal is to see if HRS-9563 can safely lower average blood pressure over 24 hours after 6 months of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-9563 injection
- What this could lead to
- If it works, this could provide a new injectable option to help control blood pressure in people with mild to moderate hypertension.
- What could go wrong
- This is an early Phase 2 trial with only 234 participants, so results may not apply to everyone. The drug may not lower blood pressure better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD TO MODERATE HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Anzhen Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100029, China
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.